Targeting cancer with peptide aptamers

Oncotarget

Volumn 2, Issue 7, 2011, Pages 557-561

  Seigneuric, Renaud ^a,b   Gobbo, Jessica ^a,b   Colas, Pierre ^c   Garrido, Carmen ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Protein Phosphorylation and Human Disease Group   (France)

Author keywords

Aptamer; Cancer; Heat shock protein; Peptide; Targeted therapy

Indexed keywords

AS 1411; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; LIPOSOME; NUCLEOLIN; PEGAPTANIB; PEPTIDE APTAMER; PROTEIN E6; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYBRID PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NANOTECHNOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; CHEMISTRY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; APTAMERS, PEPTIDE; CLINICAL TRIALS AS TOPIC; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 84856635199     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.297     Document Type: Article

References (38)

1. DeVita VT, Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008; 68:8643-8653.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46:3-26.
3. Imai K, Takaoka A. Comparing antibody and smallmolecule therapies for cancer. Nat Rev Cancer. 2006; 6:714-727.
4. Papin JA, Hunter T, Palsson BO, Subramaniam S. Reconstruction of cellular signalling networks and analysis of their properties. Nat Rev Mol Cell Biol. 2005; 6:99-111.
5. Ladner RC. Antibodies cut down to size. Nat Biotechnol. 2007; 25:875-877.
6. Lacana E, Amur S, Mummanneni P, Zhao H, Frueh FW. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther. 2007; 82:466-471.
7. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 9:767-774.
8. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004; 3:711-715.
9. Seigneuric R, L. Markey, D.S.A. Nuyten, C. Dubernet, C.T.A. Evelo, E. Finot, Garrido C. From Nanotechnology to Nanomedicine: applications to cancer research. Curr Molecular Medicine 10(7):640-52. 2010.
10. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 1996; 380:548--550.
11. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D, Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget. 2:298-304.
12. Borghouts C, Kunz C, Groner B. Peptide aptamers: recent developments for cancer therapy. Expert Opin Biol Ther. 2005; 5:783-797.
13. Baines IC, Colas P. Peptide aptamers as guides for smallmolecule drug discovery. Drug Discov Today. 2006; 11:334-341.
14. Ladner RC. Constrained peptides as binding entities. Trends Biotechnol. 1995; 13:426-430.
15. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103:6315-6320.
16. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008; 26:74-85.
17. Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006; 5:123-132.
18. Soundararajan S, Wang L, Sridharan V, Chen W, Courtenay-Luck N, Jones D, Spicer EK, Fernandes DJ. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009; 76:984-991.
19. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A. 2000; 97:6693-6697.
20. Kunz C, Borghouts C, Buerger C, Groner B. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Mol Cancer Res. 2006; 4:983-998.
21. Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, Carloni P, Del Sal G. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res. 2008; 68:6550-6558.
22. Rerole AL, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C. Peptides and Aptamers Targeting HSP70: A Novel Approach for Anticancer Chemotherapy. Cancer Res. 2011.
23. Gibert B, Hadchity E, Czekalla A, Aloy MT, Colas P, Rodriguez-Lafrasse C, Arrigo AP, Diaz-Latoud C. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene. 2011.
24. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009; 101:708-720.
25. Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol. 5:65-72.
26. Fleming TR, DeMets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? Ann Intern Med. 1996:605-613.
27. Johnson S, Evans D, Laurenson S, Paul D, Davies AG, Ko Ferrigno P, Walti C. Surface-immobilized peptide aptamers as probe molecules for protein detection. Anal Chem. 2008; 80:978-983.
28. Getting personal. Nature. 2011; 473:253.
29. Weinberg RA: The Biology of Cancer. New York: Garland Scientific; 2006.
30. Weissmann G. Claude Bernard and Judah Folkman: nothing makes sense in medicine except in the light of biology. Faseb J. 2008; 22:943-946.
31. Seigneuric RG, Chasse JL, Auger P, Bardou A. Simulated interactions between a Class III antiarrhythmic drug and a figure 8 reentry. Acta Biotheor. 2005; 53:265-275.
32. Catterall WA. Ion channel voltage sensors: structure, function, and pathophysiology. Neuron. 2010; 67:915-928.
33. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009; 8:982-1001.
34. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002; 298:1912-1934.
35. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today. 2005; 10:839-846.
36. Colas P. The eleven-year switch of peptide aptamers. J Biol. 2008; 7:2.
37. Sporn MB. Perspective: The big C - for Chemoprevention. Nature. 2011; 471:S10-11.
38. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordonez GR, Mudie LJ, Latimer C et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 463:184-190.